Molecular Cancer Therapeutics

A Journal of the American Association for Cancer Research

Volume 3, Number 8 **August 2004**

Articles

contents continued

contents continued

Minireviews



On the Cover

Rapid internalization of TMEFF2 in prostate cancer cells in culture. The *TMEFF2* gene encodes a plasma membrane protein with limited normal tissue distribution and high overexpression in prostate cancer. The images show binding of a specific monoclonal antibody (mAb) to TMEFF2 protein on the surface of prostate cancer cells at 4°C (*upper panel*), and the rapid and efficient internalization of the mAb-antigen complex at 37°C (*lower panel*). Internalization is essential for an antibody-drug-conjugate (ADC) approach to cancer therapy, where drug release is dependent on lysosomal protease activity. A cathepsin B sensitive anti-TMEFF2 ADC was used to show specific cell killing and antitumor effects in prostate cancer xenograft models, validating it as a potential new therapy for the treatment of prostate cancer. For details, see Afar et al. in this issue.

Molecular Cancer Therapeutics is abstracted or indexed in Chemical Abstracts, Index Medicus, MEDLINE, BIOSIS Previews, and Current Contents. *Molecular Cancer Therapeutics* is also published online. Please visit http://mct.aacrjournals.org.